Long Term Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Subjects [EXTENSION OF PROFILE 700021577].

Trial Profile

Long Term Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Subjects [EXTENSION OF PROFILE 700021577].

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Sep 2015 Results published in the Vaccine.
    • 21 Sep 2013 Planned number of patients changed from 166 to 167 as reported by European Clinical Trials Database record.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top